Arcus Biosciences Q3 2026 net loss narrows 5% to $128 million; revenues drop 65% to $9 million
RCUS•Arcus Biosciences’ third-quarter 2026 net loss narrowed 5% year over year to $128 million, while revenue fell 65% to $9 million. The company had $694 million in cash, cash equivalents and marketable securities at September 30 and expects full-year GAAP revenue of $70 million to $75 million.
1. Quarterly results and outlook
Research and development expenses declined 17% year over year to $117 million, primarily due to lower late- and early-stage development activity. Arcus said funding, including its October equity financing, supports operations into 2029. Enrollment in the casdatifan Phase 3 PEAK-1 trial is expected to finish within two to three months, and the first-line PEAK-20 trial is expected to begin by year-end 2026.
